CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Unlock the potential of your credit cards with various methods to earn more points. Explore effective strategies to enhance your rewards.
27,707 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Casey’s General Stores prepares to report Q4 results after the bell, with analysts weighing margins in prepared foods...
A Digi International VP sold a stake amid a fast-changing IoT landscape. This article breaks down what such insider m...
Retail traders are driving a surge in futures activity as CME Group reports record May volume. This piece explains ho...
Fox agreed to buy Roku for $22 billion, sending Roku stock to four-year highs and triggering debate over how the deal...
Chevron stock has cooled from a $209 peak, leaving investors weighing dividend coverage, cash flow, and growth amid v...
Interest in Rocket Lab stock is rising as the small-launch market tightens. This guide breaks down why everyone is ta...
Markets have danced to a rhythm of inflation worries and policy signals. This article breaks down what president dona...
Netflix has cooled off, and rumors about Warner Bros. and Roku fueled debate. This guide analyzes whether the pullbac...
Rhode Island housing reform advocates take stock after a truncated 2026 session ended without top-priority reform, se...
As 2026 markets grind higher on slower inflation, investors debate whether a simple, low-cost core holding like VOO r...
Investors are shifting from FXI to a South Korea-focused ETF to capture the AI hardware boom, citing lower costs and ...